HOUSTON, Jan. 30, 2018 /PRNewswire/ -- RadiaDyne announces the first commercial sale in New York City, New York of their upcoming OARtrac system to one of the recognized leaders in radiation delivery for cancer treatment. "We are excited about the early interest and momentum of this new technology, and the
ABOUT THE OARTRAC PLATFORM. OARtrac® is the first of its kind patient radiation dose monitoring system which provides gold standard accuracy, real-time pinpoint measurement, and proprietary intracavitary delivery devices to physically measure radiation dose during photon external beam therapy and HDR brachytherapy radiation treatments. OARtrac® provides critical radiation dose feedback which helps facilitate adaptive radiotherapy for true personalized treatment with the goal to reduce side effects and offer better clinical outcomes.
ABOUT RADIADYNE: RadiaDyne is a privately held medical diagnostic and device company focused on patient dose monitoring technology to improve cancer treatment outcomes. RadiaDyne designs and innovates specialized sensor technology and treatment devices which assist Radiation Oncologists in delivering radiation dose to the cancerous targets, while minimizing damage to the surrounding healthy tissue. RadiaDyne is the pioneer in developing and offering real-time patient dose monitoring systems through their patented OARtrac® system.
View original content:http://www.prnewswire.com/news-releases/radiadyne-announces-first-commercial-sale-milestone-of-their-oartrac-patient-dose-monitoring-system-to-leading-cancer-center-300590239.html
Subscribe to our Free Newsletters!
Mastocytosis is a rare condition marked by accumulation of mast cells under the skin and various ...
Lusutrombopag is used to treat abnormally low platelet counts (thrombocytopenia) in adult patients ...
Stereotypic movement disorder (SMD) is a motor disorder, associated with neurodevelopmental ...View All